Skip to main content
. 2015 Mar 19;56(3):1956–1964. doi: 10.1167/iovs.14-16144

Figure 2.

Figure 2

PF-4var/CXCL4L1 prevents diabetes-induced blood–retinal barrier (BRB) breakdown. Treatment with 50 ng intravitrial PF-4var/CXCL4L1 in one eye and 18.75 μg bevacizumab in the contralateral eye in diabetic rats. The BRB breakdown was quantified with the FITC-conjugated dextran technique. Bars represent the mean ±SD of six or seven rats in each group. Diabetic, PBS-injected diabetic eye; D+ bevacizumab, bevacizumab-injected diabetic eye; D+PF-4var/CXCL4L1, PF-4var/CXCL4L1-injected diabetic eye. Each retina was subsampled and analyzed at least three times. Results are expressed as mean ± SD of at least six rats in each group. *P < 0.05 compared to normal, #P < 0.05 compared to diabetes.